Beijing Wantai Biological Pharmacy Enterprise (603392.SH): Lyophilized recombinant respiratory syncytial virus vaccine (CHO cell) approved for clinical trials.
Wantai Biological Pharmacy Enterprise (603392.SH) announced that recently, its wholly-owned subsidiary Wantai Canghai received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for the lyophilized recombinant respiratory syncytial virus vaccine (CHO cell). Approval was granted to conduct clinical trials for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) infection in people aged 60 and above.
Beijing Wantai Biological Pharmacy Enterprise (603392.SH) announced that recently, its wholly-owned subsidiary Wantai Canghai received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for the lyophilized recombinant respiratory syncytial virus vaccine (CHO cell). It is approved to conduct clinical trials for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) infection in people aged 60 and above.
Related Articles
Midea Group Co., Ltd (00300) repurchased 1,075,300 A shares on October 12 for approximately RMB 89.9143 million.
ESSEX BIO-TECH (01061) repurchased 30,000 shares for HK$61,800 on October 12.
CHINA HONGBAO (08316) changes its name to "Sujiao Suidao Life Holdings Limited"
Midea Group Co., Ltd (00300) repurchased 1,075,300 A shares on October 12 for approximately RMB 89.9143 million.
ESSEX BIO-TECH (01061) repurchased 30,000 shares for HK$61,800 on October 12.
CHINA HONGBAO (08316) changes its name to "Sujiao Suidao Life Holdings Limited"
